Establishment Labs Holdings, Inc.

Establishment Labs Holdings, Inc. has achieved a new 52-week high, reflecting a substantial increase in its stock price over the past year, significantly outpacing the S&P 500. With a market capitalization of USD 1,644 million, the company operates in a competitive biotechnology sector, despite facing financial challenges.

Establishment Labs Holdings, Inc. has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company has seen significant growth over the past year, despite being loss-making, with notable financial metrics indicating a leveraged position and high valuation relative to its book value.

Establishment Labs Holdings, Inc. has achieved a new 52-week high, reflecting a significant performance increase over the past year. With a market capitalization of USD 1,644 million, the company faces challenges, including a high debt-to-equity ratio and negative return on equity, while competing in the pharmaceuticals and biotechnology sector.

Establishment Labs Holdings, Inc. has experienced notable stock performance, significantly outperforming the S&P 500 over various time frames. The company reported substantial financial growth, including a remarkable increase in net profit and sales. High institutional ownership reflects strong confidence from investors in the company's potential.

Establishment Labs Holdings, Inc. has achieved a new 52-week high, reflecting a significant increase in its stock performance over the past year. With a market capitalization of USD 1,644 million, the company operates in a competitive sector, demonstrating resilience despite being loss-making and showcasing strong investor confidence.

Establishment Labs Holdings, Inc. achieved a new 52-week high of USD 78.25, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen significant growth over the past year, despite being loss-making, with notable financial metrics indicating a premium valuation relative to its book value.

Establishment Labs Holdings, Inc. has seen notable stock activity, rising significantly today despite a broader market decline. The company has achieved substantial gains over the past week and month, but it faces challenges such as operating losses and a high debt-to-EBITDA ratio, indicating potential financial difficulties ahead.

Establishment Labs Holdings, Inc. achieved a new 52-week high of USD 54.00 on October 29, 2025, reflecting a year-over-year performance of 7.88%. The company, with a market cap of USD 1,124 million, operates at a loss and has a high debt-to-equity ratio, indicating significant reliance on debt financing.

Establishment Labs Holdings, Inc. has seen significant stock gains recently, outperforming the S&P 500 over various timeframes. Despite this positive momentum, the company faces ongoing challenges, including operating losses and a high debt-to-EBITDA ratio, highlighting a complex financial landscape.

Establishment Labs Holdings, Inc. has recently seen a revision in its evaluation, reflecting changes in technical indicators. The stock price is currently $41.16, with significant volatility over the past year. Performance metrics show mixed results compared to the S&P 500, highlighting the company's fluctuating market position.

Establishment Labs Holdings, Inc. has experienced notable stock fluctuations, closing at $41.43 with a 52-week range of $26.55 to $50.85. Technical indicators show mixed signals, and the stock has underperformed the S&P 500 over the past year, though it has outperformed the index over five years.